NGNE
Neurogene Inc.Healthcare·Biotechnology
$28.34
$448M market cap
Revenue
$0.0M
Free Cash Flow
$-43.2M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
2-Year Price History
$27.71-26.3%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -32.5 | -33.4 | -30.9 | -26.1 | -26.4 | -0.3 | 243.2 | 9.1 | 22.3 | -199.8% | -- | -- |
| Act | 2025-Q4 | 0.0 | -26.7 | -27.5 | -24.7 | -16.7 | -16.8 | -0.1 | 269.0 | 9.9 | 15.5 | -114.8% | -26742.0x | -- |
Valuation & Metrics
Market Stats
Price$28.34
Market Cap$448M
Enterprise Value$214M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-9.6%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-55.7M
Free Cash Flow$-43.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-157.3%
WC Change % Rev0.0%
Interest Coverage-59237.0x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.7M
Days to Cover19.9
Change (vs Prior)-7.3%
Need at least 2 settlement dates for chart
Employees
Headcount107
Revenue / Employee$0
Gross Profit / Employee$-15,336
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
67.3%(+30.3% YoY)
85 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
10.9%(+3.9% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.0%(-0.0% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Samsara BioCapital, LLC | $34.6M | $20.29 | +$0 | +$0 | -3.9% | $1.03B |
| Redmile Group, LLC | $29.4M | $21.12 | +$0 | +$3.1M | -5.7% | $1.51B |
| Casdin Capital, LLC | $28.6M | $21.34 | +$2.5M | +$2.5M | -3.1% | $1.32B |
| RTW INVESTMENTS, LP | $27.5M | $42.49 | +$0 | +$278K | -2.2% | $9.26B |
| EcoR1 Capital, LLC | $25.6M | $19.38 | +$0 | +$0 | -4.8% | $2.34B |
| BlackRock, Inc.Passive | $20.3M | $39.39 | +$1.2M | −$7.9M | -0.2% | $5.69T |
| BAKER BROS. ADVISORS LP | $20.0M | $15.76 | +$0 | −$10.0M | -0.4% | $16.13B |
| Trails Edge Capital Partners, LP | $15.8M | $20.60 | −$45K | +$15.8M | +12.7% | $425M |
| BALYASNY ASSET MANAGEMENT LLC | $14.5M | $17.71 | +$2.2M | +$14.5M | -0.4% | $48.01B |
| TORONTO DOMINION BANK | $13.7M | $13.81 | +$0 | +$8.9M | -0.3% | $51.69B |
| JENNISON ASSOCIATES LLC | $10.6M | $21.13 | −$109K | +$8.5M | +2.7% | $145.31B |
| ArrowMark Colorado Holdings LLC | $10.6M | $18.78 | −$1.1M | +$1.7M | -4.3% | $3.74B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $10.4M | $20.16 | +$10.4M | +$10.4M | — | $4.04T |
| GREAT POINT PARTNERS LLC | $10.1M | $19.51 | +$3.0M | +$585K | -4.6% | $408M |
| CITADEL ADVISORS LLC | $7.8M | $20.20 | +$460K | +$7.5M | -0.4% | $138.22B |
| FMR LLC | $7.7M | $34.17 | +$5.1M | −$1.6M | -0.0% | $1.89T |
| STATE STREET CORPPassive | $6.3M | $33.23 | +$105K | +$1.7M | -0.2% | $2.89T |
| MORGAN STANLEY | $5.8M | $25.07 | −$1.7M | −$18K | -0.3% | $1.65T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $5.6M | $35.09 | +$591K | +$396K | +2.3% | $1.61T |
| MILLENNIUM MANAGEMENT LLC | $4.1M | $22.62 | +$2.7M | +$945K | -0.5% | $127.40B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-1.65%
avg per quarter
Holders (ex-self)
-1.63%
excl. this stock
Buyers (this Q)
-1.30%
56 buyers · $0.03B in
Sellers (this Q)
-0.14%
18 sellers · $0.01B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-21.9%
how holders react when this stock falls
On quiet Qs
+28.1%
−10% to +10% baseline
On rallies (+10%+)
-12.1%
how they react when this stock rises
Holders' portfolio flow this Q
+2.4%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.3%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-5.0%
Holder mid (any stock)
-3.3%
Holder rally (any stock)
-6.1%
Biggest decreases this quarter
Logos Global Management LPexited−$4.0MMORGAN STANLEY−$1.7Mα-0.3GOLDMAN SACHS GROUP INC−$1.1Mα-0.2ArrowMark Colorado Holdings LLC−$1.1Mα-4.3Trexquant Investment LPexited−$892KD. E. Shaw & Co., Inc.exited−$831KWalleye Capital LLCexited−$744KSquarepoint Ops LLCexited−$669KADAR1 Capital Management, LLCexited−$631KExodusPoint Capital Management, LPexited−$600K
New buyers this quarter
Top-5 holders · 42.6%
Samsara BioCapital, LLC--
Redmile Group, LLC--
Casdin Capital, LLC--
RTW INVESTMENTS, LP--
EcoR1 Capital, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
EcoR1 Capital, LLC1.3MSamsara BioCapital, LLC1.7MGREAT POINT PARTNERS LLC500KRTW INVESTMENTS, LP1.4MRedmile Group, LLC1.5MJANUS HENDERSON GROUP PLC—FMR LLC383KCasdin Capital, LLC1.4MCormorant Asset Management, LLC—Avidity Partners Management LP—
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| SRRK | Scholar Rock Holding Corporation | 3 | 167.68× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$69.0014350.0%
Last Year (2 analysts)$57.0010110.0%
Current Price$28.34
Analyst Ratings
5
1
Buy: 5Hold: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$794K
7 txns · 4 insiders · 31,980 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-06 | SELL | Cvijic Christine Mikail | director, officer: President and CFO | 9,600 | $31.25 | $300K | $2.93M |
| 2026-03-26 | SELL | Cvijic Christine Mikail | officer: President and CFO | 2,558 | $21.62 | $55K | $2.23M |
| 2026-03-26 | SELL | Jordan Julie | officer: Chief Medical Officer | 828 | $21.89 | $18K | $273K |
| 2026-03-26 | SELL | McMinn Rachel | director, officer: Chief Executive Officer | 3,352 | $22.07 | $74K | $29.68M |
| 2026-03-13 | SELL | Cobb Stuart | officer: Chief Scientific Officer | 6,797 | $20.81 | $141K | $635K |
| 2026-03-13 | SELL | Cvijic Christine Mikail | officer: President and CFO | 4,045 | $20.81 | $84K | $2.20M |
| 2026-02-27 | SELL | Cvijic Christine Mikail | officer: President and CFO | 4,800 | $25.11 | $121K | $2.76M |
Order Flow (FINRA, ~3w lag)
11.8%retail-7.8pp
33.2%dark+5.6pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Neurogene Inc.: Massive Dilution Engine Powering a High-Burn Gene Therapy Pipeline
Overall Risk
6/10
Fraud
2/10
Dilution
9/10
Insolvency
3/10
Earnings Overstated
2/10
Hidden Liabilities
4/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
7/10